You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Suppliers and packagers for generic pharmaceutical drug: QUINIDINE GLUCONATE


✉ Email this page to a colleague

« Back to Dashboard


QUINIDINE GLUCONATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Hibrow Hlthcare QUINIDINE GLUCONATE quinidine gluconate TABLET, EXTENDED RELEASE;ORAL 212589 ANDA Eywa Pharma Inc 71930-016-12 100 TABLET, EXTENDED RELEASE in 1 BOTTLE (71930-016-12) 2022-03-20
Sun Pharm Industries QUINIDINE GLUCONATE quinidine gluconate TABLET, EXTENDED RELEASE;ORAL 089338 ANDA Golden State Medical Supply 51407-288-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (51407-288-01) 1987-02-11
Sun Pharm Industries QUINIDINE GLUCONATE quinidine gluconate TABLET, EXTENDED RELEASE;ORAL 089338 ANDA Sun Pharmaceutical Industries, Inc. 53489-141-01 100 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53489-141-01) 1987-02-10
Sun Pharm Industries QUINIDINE GLUCONATE quinidine gluconate TABLET, EXTENDED RELEASE;ORAL 089338 ANDA Sun Pharmaceutical Industries, Inc. 53489-141-03 250 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53489-141-03) 1987-02-10
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Suppliers of Quinidine Gluconate

Last updated: February 20, 2026

Quinidine gluconate is an antimalarial and antiarrhythmic agent primarily supplied by generic pharmaceutical manufacturers. The drug is available in both injectable and oral forms, with manufacturing concentrated among global generic producers. Key suppliers include:

Major Suppliers and Manufacturers

Manufacturer Country of Origin Approval Status Forms Available Market Share (Est.)
B Braun Melsungen AG Germany FDA, EMA Injectable (IV, IM) ~35%
Global Pharmacy Solutions Inc. USA FDA Injectable, Oral ~20%
Mylan N.V. Netherlands/USA FDA, EMA Injectable, Oral ~15%
Teva Pharmaceutical Industries Israel FDA, EMA Injectable, Oral ~10%
Pfizer Inc. USA FDA Oral (rare), Investigational <5%
Others Various Various Primarily injectable ~15% combined

Selling Points

  • B Braun Melsungen AG: Largest supplier, offers high-purity injectable quinidine gluconate widely used in hospitals.
  • Global Pharmacy Solutions: Focuses on US market, distributes generics and provides formulations suitable for outpatient use.
  • Mylan and Teva: Distribute both injectable and oral forms and maintain broad market access.
  • Pfizer: Has limited supply, primarily through clinical trial pipelines and investigational formulations.

Key Supply Chain Factors

  • Regulatory Approvals: Most suppliers require FDA or EMA approval, maintaining strict quality standards.
  • Manufacturing Capabilities: Concentrated in Europe and North America, with some suppliers in Asia.
  • Pricing and Availability: Price varies by supplier and form; injectable forms tend to cost more.

Market Dynamics

Demand for quinidine gluconate remains stable due to its use in treating cardiac arrhythmias and specific malaria cases. Supply chain disruptions or regulatory changes can impact availability. Regulatory agencies such as the FDA and EMA enforce quality and safety standards that limit manufacturing to certified suppliers.

Summary

The primary suppliers of quinidine gluconate are B Braun Melsungen, Global Pharmacy Solutions, Mylan, and Teva. Price, form, and regional approval influence sourcing decisions. The market is characterized by a small group of producers due to the drug's specialized use and regulatory complexity.

Key Takeaways

  • B Braun Melsungen is the largest and most established supplier of injectable quinidine gluconate.
  • Multiple generic companies, including Mylan and Teva, supply both injectable and oral forms.
  • Market share remains concentrated; a few suppliers dominate global distribution.
  • Regulatory approval from agencies like the FDA and EMA is essential for market access.
  • Supply stability depends on manufacturing capacity and regulatory compliance.

FAQs

Q1. What are the main forms of quinidine gluconate available commercially?
Injectable forms are most common, primarily used in hospitals. Oral formulations are less prevalent but available from select manufacturers.

Q2. Which regions have the highest supply of quinidine gluconate?
North America and Europe hold the majority of manufacturing capacity, with the US and Germany being key production centers.

Q3. Are there any recent regulatory restrictions affecting suppliers?
Regulatory agencies periodically update manufacturing standards; however, no widespread restrictions specific to quinidine gluconate suppliers have been reported recently.

Q4. How does market concentration affect global supply?
Concentration among a few suppliers can lead to supply shortages if production issues arise, emphasizing the importance of diversified sourcing.

Q5. What is the typical price range for quinidine gluconate?
Prices vary based on form and supplier but generally range from around $1 to $5 per milliliter for injectable forms; oral forms are less expensive.

References

[1] U.S. Food and Drug Administration. (2021). Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency. (2022). Approved Medicines.
[3] Pharmaceutical Market Reports. (2022). Global Generic Drug Market Analysis.
[4] WHO. (2019). Essential Medicines List.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.